Suppliers / Shaanxi Hanjiang Pharmaceutical Group

Shaanxi Hanjiang Pharmaceutical Group

China 18 employees Updated 9 July 2026

Shaanxi Hanjiang Pharmaceutical Group is an API manufacturer based in China. It holds one active US drug master file and 9 valid CEPs across a filed portfolio of 7 molecules. Its most recent recorded inspection, by US FDA, closed on 15 July 2016 as VAI.

1
active US DMFs
9
valid CEPs
4
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 15 July 2016 VAI US FDA
  • 13 December 2013 VAI US FDA
  • 14 October 2010 NAI US FDA
  • 21 November 2008 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hanzhong City, China Not on file
Hanzhong, China Not on file
Hanzhong City, China Not on file
China, China 3003011617

What they file, and where

Molecule Regulators Docs
Progesterone EDQM, SFDA (Saudi Arabia) 3
Estradiol EDQM 2
Mebendazole EDQM, US FDA 2
Racecadotril EDQM, SFDA (Saudi Arabia) 2
Fenbendazole For Veterinary Use EDQM 1
Flubendazole EDQM 1
Oxfendazole For Veterinary Use EDQM 1

Also appears on these molecule pages

Estradiol API Mebendazole API Progesterone API

Comparing suppliers?

Choose your molecules and target markets. Shaanxi Hanjiang Pharmaceutical Group comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 15 July 2016.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability